Sugi Predict

Sugi Predict / Compounds / SCHEMBL371952

SCHEMBL371952

SCHEMBL371952

COc1cc2nccc(Oc3ccc(N(C(=O)C4(C(N)=O)CC4)c4ccccc4)cc3)c2cc1OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKB Q96GD4 4/20 0.58
▸ FLT3 P36888 2/20 0.58
▸ PDGFRA P16234 6/20 0.56
▸ KDR P35968 5/20 0.56
▸ MET P08581 4/20 0.54
▸ AXL P30530 4/20 0.54
▸ KIT P10721 3/20 0.54
▸ AURKA O14965 2/20 0.54
▸ ABL1 P00519 2/20 0.54
▸ LCK P06239 2/20 0.54
▸ LYN P07948 2/20 0.54
▸ FLT1 P17948 2/20 0.54
▸ TEK Q02763 2/20 0.54
▸ MERTK Q12866 2/20 0.54
▸ RIPK2 O43353 1/20 0.54
▸ ABCB11 O95342 1/20 0.54
▸ EGFR P00533 1/20 0.54
▸ ERBB2 P04626 1/20 0.54
▸ NTRK1 P04629 1/20 0.54
▸ PGR P06401 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31105476 1.00 AURKB (0.58) AURKBFLT3PDGFRAKDRMET
SCHEMBL38660033 0.93 AURKB (0.56) AURKBFLT3PDGFRAKDRMET
SCHEMBL29883010 0.92 MET (0.66) AURKBFLT3PDGFRAKDRMET
SCHEMBL372017 0.92 MET (0.66) AURKBFLT3PDGFRAKDRMET
SCHEMBL31105478 0.90 KDR (0.55) AURKBFLT3PDGFRAKDRMET
SCHEMBL372251 0.90 AURKB (0.50) AURKBFLT3PDGFRAKDRMET
Pyruvate SCHEMBL29195420 0.90 MET (0.61) AURKBFLT3PDGFRAKDRMET
Glutarate SCHEMBL29195414 0.87 MET (0.58) AURKBFLT3PDGFRAKDRMET
SCHEMBL372191 0.87 AXL (0.49) AURKBFLT3PDGFRAKDRMET
SCHEMBL372047 0.86 MET (0.48) AURKBFLT3PDGFRAKDRMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP claimed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US claimed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
EP-3329918-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2018-06-06 — — EP claimed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US claimed
EP-2409704-B1 c-Met modulators and methods of use EXELIXIS INC (US) 2017-09-20 — — EP claimed
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 — — US claimed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 — — US claimed
US-20140155396-A1 C-Met Modulators and Method of Use EXELIXIS, INC. 2014-06-05 — — US claimed
US-20120022065-A1 C-Met Modulators and Method of Use EXELIXIS, INC. (US) 2012-01-26 — — US claimed
EP-2409704-A2 c-Met modulators and methods of use Exelixis Inc. (US) 2012-01-25 — — EP claimed
EP-2101759-A1 METHODS OF USING MEK INHIBITORS Exelixis, Inc. (US) 2009-09-23 — — EP claimed
WO-2009017838-A2 COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS EXELIXIS, INC. (US) 2009-02-05 — — WO claimed
WO-2008076415-A1 METHODS OF USING MEK INHIBITORS EXELIXIS, INC. (US) 2008-06-26 — — WO claimed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US claimed
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET AURKB 790/4885FLT3 7/4885PDGFRA 63/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET AURKB 790/4885FLT3 7/4885PDGFRA 63/4885
US-20120022065-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 AURKB 559/4885FLT3 7/4885PDGFRA 182/4885
US-20140155396-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 AURKB 559/4885FLT3 7/4885PDGFRA 182/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET AURKB 790/4885FLT3 7/4885PDGFRA 63/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET AURKB 790/4885FLT3 7/4885PDGFRA 63/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET AURKB 790/4885FLT3 7/4885PDGFRA 63/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 AURKB 559/4885FLT3 7/4885PDGFRA 182/4885
US-20160185725-A1 c-Met Modulators and Method of Use FLT4, MET, FLT1 AURKB 559/4885FLT3 7/4885PDGFRA 182/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET AURKB 790/4885FLT3 7/4885PDGFRA 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.